U.S. Acne Treatment Market to Exhibit 4.7% CAGR from 2023 to 2030; Rising Prevalence, New Drug Innovations, and Favorable Reimbursement Policies Fuel Market Growth

The U.S. acne treatment market size was valued at USD 5.00 billion in 2022. The market is projected to grow from USD 5.28 billion in 2023 to USD 7.27 billion by 2030, exhibiting a CAGR of 4.7% during the forecast period. Fortune Business Insights™ presents this information in its report titled “U.S. Acne Treatment Market Size, Share & COVID-19 Impact Analysis, By Product Type (Retinoids, Antibiotics, Isotretinoin, and Others), By Treatment Modality (Oral and Topical), By Age Group (10 to 17, 18 to 44, 45 to 64, and 65 and Above), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and Country Forecast, 2023-2030”.

The U.S. acne treatment market share is expected to grow due to the increasing prevalence of acne in the population and the introduction of new drugs to meet the rising demand. With acne being a common skin condition affecting millions of Americans, there is a growing awareness and demand for effective acne treating options. The adoption of cosmeceuticals as a complementary treatment approach is also contributing to the market's growth. The growth of the market is further supported by favorable reimbursement policies for the treatment of skin conditions, including psoriasis.

Decline in Revenue and Disrupted Healthcare Services Amid Pandemic Curbed Market

The market faced challenges during the COVID-19 pandemic, with a decline in revenue in 2020 due to postponed services and limited product availability. During the financial year 2019-2020, Johnson & Johnson Services, Inc. experienced a decline of 3.1% in revenue within its skin health segment. This decline can be attributed to various factors, including the impact of the COVID-19 pandemic, which disrupted healthcare services and affected the demand for skin health products. However, as restrictions eased and healthcare facilities reopened in 2021, patient visits increased, leading to a resurgence in demand for acne treating drugs.

Entry into In-Office Acne Treatment Solutions Strengthens STRATA's Presence and Market Expansion

STRATA Skin Sciences, Inc. made an announcement about its acquisition of assets related to Theravant Corporation's TheraClear System in January 2022. This acquisition marks STRATA's entry into the acne treating market, as Theravant's FDA-cleared system offers an in-office treatment solution for various common forms of acne. The acquisition is expected to facilitate STRATA's expansion and enhance its presence in the acne treating segment.

In-Home Diagnostics and Teledermatology Brands such as NavaMD by LifeMD, Inc. Propel Market Expansion

The adoption of telemedicine for diagnosing and treating patients with acne has been recognized by medical associations and the U.S. government as an effective model. This has resulted in a rapid shift of patients toward telemedicine, supported by favorable reimbursement policies. Market players are also introducing in-home diagnostics and consultation in dermatology, further driving market growth. LifeMD, Inc. launched NavaMD in 2021, a personalized teledermatology brand clinic offering services to patients across all 50 states, showcasing the industry's commitment to expanding telehealth services in dermatology.

However, high and side effects associated with the treatment products of acne may potentially limit the U.S. acne treatment market growth.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/u-s-acne-treatment-market-106565

Competitive Landscape, Collaborations, and Product Launches Drive Growth

The market features a competitive landscape with a mix of large, mid-size, and small manufacturers offering various products for treating acne. GALDERMA and Sol-Gel Technologies, Ltd. signed exclusive license agreements in June 2021 for the commercialization of EPSOLAY and TWYNEO, demonstrating collaborations in bringing advanced investigational drug products to the market. Market players are also actively launching new products to meet the growing demand for acne treatment and expand their customer base in the U.S., showcasing their commitment to innovation and meeting consumer needs.

Notable Industry Development

• September 2021: Incyte announced the approval of the U.S. Food and Drug Administration of Opzelura for the treatment of non-immunocompromised atopic dermatitis. The brand is the first JAK inhibitor to be approved in the U.S. The cream is indicated for patients aged 12 years and above who do not respond to other topical products.

List of Companies Profiled in the Report:

• Bausch Health Companies Inc. (Canada)
• GALDERMA (Switzerland)
• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• GlaxoSmithKline Plc (U.K.)
• Allergan (Ireland)
• Mayne Pharma Group Limited (Australia)
• Sun Pharmaceutical Industries Ltd. (India)
• Reckitt Benckiser Group PLC (U.K.)
• Padagis (U.S.)
• Almirall, S.A (Spain)

Further Report Findings

• By product type, the market is categorized into retinoids, antibiotics, isotretinoin, and others. The dominant segment in 2022 was antibiotics holding a significant share of 45.2%. The growth of the segment is driven by the preference of dermatologists and the availability of these products.
• In terms of treatment modality, the topical segment is projected to have the highest growth rate during the study period. This can be attributed to lower side effects and the introduction of new acne treatment products by key manufacturers.

Table of Segmentation